Vivacitas Oncology to Present Phase 2 Clinical Efficacy and Safety Data on AR-67 in Glioblastoma Multiforme (GBM) at the Society for NeuroOncology

Vivacitas Oncology to Present Phase 2 clinical efficacy and safety
data on AR-67 in Glioblastoma Multiforme (GBM) at the
Soceiety for NeuroOncology (SNO) on November 22, 2019

The team adds Sean Phillips as its Director of Investor Relations

[WALNUT CREEK, CALIFORNIA, NOVEMBER 20, 2019] – Vivacitas Oncology, Inc.
(“Vivacitas” or the “Company”), a private healthcare company focused in oncology drug
development continues to expand its activities on its lead drug AR-67.

The company plans to present a poster at the Society of NeuroOncology (SNO) on November
22nd between 7:30-9:30 PM, highlighting the Phase 2 clinical efficacy and safety of its lead drug
candidate, AR-67, in patients with Glioblastoma Multiforme (GBM). The company also intends
to plan its registrational clinical trial based on this data for the potential approval of AR-67 in
GBM patients.

The company has also hired Mr. Sean Phillips at its Director of Investors Relations. Previously

Mr. Phillips worked at well-established companies such as JP Morgan Chase, Capital One and
Citibank. After spending more than 12 years in commercial banking and private equity with

various enterprises, he knows what drives businesses and how to expand on brand awareness. At
Vivacitas, Mr. Phillips will be responsible for marketing strategy, building rapport with
investors, clients, and vendors while also managing capital needs of the company.

If you would like more information on Vivacitas Oncology, Inc please visit our
website: or call Sean Phillips at 773-679-8603.


A privately held biopharmaceutical company co-founded in 2015 by Dr. Joseph Rubinfeld and
Infusion 51a, LP. Vivacitas is focused on acquiring mid-to-late-stage oncology assets with the
goal to make the chemotherapy more effective for patients.

For further information please visit

Forward-Looking Statements
Certain statements, other than purely historical information, including estimates, projections,
statements relating to our business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are forward-looking statements. These
forward-looking statements generally are identified by the words “believes,” “project,” “expects,”
“anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will
continue,” “will likely result,” and similar expressions. Forward-looking statements are based on
current expectations and assumptions that are subject to risks and uncertainties which may cause
actual results to differ materially from the forward-looking statements. Our ability to predict
results or the actual effect of future plans or strategies is inherently uncertain. Factors which
could have a material adverse effect on our operations and future prospects on a consolidated
basis include, but are not limited to: changes in economic conditions, legislative/regulatory
changes, availability of capital, interest rates, competition, and generally accepted accounting
principles. These risks and uncertainties should also be considered in evaluating forward-looking
statements and undue reliance should not be placed on such statements.